Concepedia
Statistics
Publications
28
Citations
3.7K
H-Index
24
Active since
1984
Affiliations
Novartis (United States)(Current)
Novartis (Switzerland)
University of California, Irvine
University College London
Tris Pharma (United States)
Ravi Anand is an author at Novartis (United States) specializing in medicine, neurology, and dementia.
Top concepts
MedicineNeurologyDementiaAlzheimer's DiseaseTreatmentPsychiatryHealthPharmacologyPsychopathologySocial Sciences
Publications per year
1984–2016
Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study
Ian G. McKeith, Teodoro del Ser, PierFranco Spano et al. · The Lancet · 2000 · 1.2K citations
Alzheimer's Disease, Geriatrics, Placebo-controlled International Study +10
A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease
Martin R. Farlow, Ravi Anand, John Messina et al. · European Neurology · 2000 · 327 citations
Two‐year, randomized, controlled study of safinamide as add‐on to levodopa in mid to late Parkinson's disease
Rupam Borgohain, József Attila Szász, Paolo Stanzione et al. · Movement Disorders · 2014 · 230 citations · Full text
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations
Anthony H.V. Schapira, Susan H. Fox, Robert A. Hauser et al. · JAMA Neurology · 2016 · 207 citations
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease
Steven G. Potkin, Ravi Anand, Kirsten Fleming et al. · The International Journal of Neuropsychopharmacology · 2001 · 159 citations · Full text
1–5 of 28